Do you need to cycle off tesamorelin?

No published protocol calls for it. The phase 3 trials gave tesamorelin daily and continuously — 26 weeks, extended to 52 — with no scheduled breaks, and no trial has tested an on-and-off schedule. Unlike anabolic steroids, tesamorelin doesn't suppress a hormone system that needs time to recover. Duration is set by a prescriber based on response, labs and tolerability rather than a fixed calendar.

How long is a tesamorelin cycle in the studies?

The studies didn't run cycles; they ran continuous treatment periods. The two phase 3 trials treated for 26 weeks, then continued a subset for a second 26 weeks, so the longest randomized experience on record is 52 weeks of uninterrupted daily use. A meta-analysis of four trials and 909 patients, published in July 2026, concluded that the best duration is still an open research question.

What happens if you stop taking tesamorelin?

Visceral fat returns. In the 26-week extension published in AIDS in 2008, people switched from tesamorelin to placebo saw the deep abdominal fat reaccumulate, and the authors concluded the effects do not last beyond the duration of treatment. IGF-1 fell back toward where it began as well. Stopping is not a maintenance phase — it is a drift back toward baseline.

Is compounded tesamorelin FDA-approved or not?

Not in the form offered here. Egrifta is FDA-approved for HIV-associated lipodystrophy; the compounded formulation prescribed through Promise is not, and compounded medications are not reviewed by the FDA for safety, effectiveness or quality. A licensed provider may still prescribe a compounded formulation when they judge it appropriate — that decision sits between you and your doctor.

Why do prescribers talk about IGF-1 instead of cycle length?

Because IGF-1 is measurable and a calendar isn't. Tesamorelin raises IGF-1, the growth factor the liver makes in response to growth hormone, and the brand product's labeling directs prescribers to monitor it during treatment and consider stopping if it stays persistently high. Among people treated for 26 weeks, 47% were more than 2 standard deviations above the reference range and 36% were more than 3.

Tesamorelin Cycle: Why Doctors Talk About Duration

A tesamorelin cycle — eight weeks on, four weeks off, the way bodybuilding forums lay it out — is not something the research describes. That word comes from anabolic steroid practice, where stopping for a while is how people try to let their own hormone production restart. Tesamorelin doesn't create that problem, so it doesn't need that solution. In the trials it was given every day, without a break, for 26 weeks and then for 52. When it stopped, the deep abdominal fat it had reduced came back.

So a prescriber talks about how long you stay on it, and what gets checked while you are. Not about cycling.

Where the tesamorelin cycle idea comes from

Anabolic steroids suppress the body's own testosterone. Time off is meant to give that system a chance to recover, and the whole on-and-off vocabulary grew up around that one fact. People carried the word across to peptides without carrying the reason with it.

Tesamorelin sits upstream of that problem by design. It's a stabilized copy of growth-hormone-releasing hormone — the message the brain sends the pituitary gland telling it to release growth hormone. It doesn't supply the hormone. It asks for it, and the pituitary's own brake stays in the circuit.

There's nothing suppressed that a month off would rescue. And no trial has ever tested an on-and-off schedule, which means any protocol you find online with weeks and rest periods in it was written by someone rather than measured by anyone.

What the trials actually ran

Daily, continuously, for six months — and then for a year.

The main evidence comes from two phase 3 trials in adults with HIV who had built up deep abdominal fat while on antiretroviral treatment. The first, published in the New England Journal of Medicine in 2007, gave 412 people either a daily injection or a placebo for 26 weeks. Visceral fat — the deep fat packed around the organs, which is a different tissue from the softer layer just under the skin — dropped 15.2% in the treated group and rose 5% in the placebo group.

Both trials then ran a second 26 weeks. A pooled analysis of all 806 participants, published in the Journal of Clinical Endocrinology & Metabolism in 2010, found that among people who stayed on treatment the reduction held at about 17.5% below where they started, measured at week 52.

No washout. No rest weeks. If you want the dose figures themselves and how a prescriber arrives at one, how tesamorelin dosage gets set covers that ground.

What happened when people stopped

Halfway through, both trials reshuffled. Some people who had been on tesamorelin were switched to placebo for the second half — which, without anyone intending it, is the closest thing on record to a cycling experiment.

The extension results, published in AIDS in 2008, report it plainly: on discontinuation, visceral fat reaccumulated. The authors' own summary is the line to keep — the effects "do not last beyond the duration of treatment." IGF-1 slid back as well. In the brand product's labeling, the groups taken off treatment lost roughly 135 ng/mL of the IGF-1 they had gained.

That's the practical difference. On a steroid cycle, the time off is doing something for you. Here it's just time not being treated. What tesamorelin does, and what happens after goes further into the after part.

What the newest research says about how long

As of September 6, 2026, the day this article was written, the most recent pooled look at tesamorelin is a systematic review and meta-analysis published online on July 31, 2026 in the Journal of the International Association of Providers of AIDS Care. It combined four randomized trials and 909 patients. Visceral fat fell about 21 cm² more than on placebo, waist circumference about 1.6 cm, and lean body mass rose about 1.4 kg. More people stopped treatment on tesamorelin than on placebo, though that difference wasn't statistically firm.

The sentence worth sitting with is in the conclusion. The authors urge caution because of "limited data on long-term safety, optimal dosing strategies, and durability of treatment effects," and say future research should look at extended treatment duration. Nearly sixteen years after the brand product was approved, how long to stay on this is still an open question in the literature. Worth remembering the next time a schedule online settles it in one line.

A separate review in Frontiers in Endocrinology, published June 18, 2026, makes the same point from the other side. It lines the published pharmacology of growth-hormone-releasing hormone analogues up against the self-administration protocols circulating online, and sorts these compounds into tiers running from randomized-trial evidence down to no human data at all.

If a second peptide is in the prescription

Tesamorelin is sometimes prescribed alongside ipamorelin, which prompts the same growth hormone release through a different receptor. Pairing them doesn't introduce a cycling requirement — neither compound has a studied on-and-off schedule, and the combination hasn't been trialled the way tesamorelin alone has. Tesamorelin and ipamorelin together walks through what is and isn't known there.

IGF-1 is the number that gets watched

Growth hormone does much of its work through IGF-1, a growth factor the liver makes in response to it. Tesamorelin raises IGF-1 — that rise is the sign the drug is doing anything at all — and it's also the value a clinician keeps an eye on.

The prescribing information for the brand product directs prescribers to monitor IGF-1 during treatment and to consider stopping if it stays persistently high, particularly when the response hasn't been strong. The numbers behind that instruction: among people who took it for 26 weeks, 47% had IGF-1 more than 2 standard deviations above the reference range and 36% were more than 3, showing up as early as week 13. Among those who carried on to 52 weeks, 34% and 23%.

That's what a real duration decision looks like — a lab value, read at intervals, weighed against whether the treatment is doing the thing it was prescribed to do. A calendar can't do that.

What the length of treatment actually depends on

Four things, roughly. Whether it's working. What the labs say. How you're tolerating it. And what you and your prescriber agreed you were treating in the first place.

The brand product is different from a compounded one: Egrifta is FDA-approved for HIV-associated lipodystrophy, and the compounded tesamorelin prescribed here is not. Compounded medications aren't reviewed by the FDA for safety, effectiveness or quality. A licensed provider may still prescribe one when they judge it appropriate — that decision sits between you and your doctor, and what the Egrifta approval covers and what it does not sets out the regulatory side.

In practice a provider reads your history, may ask for lab work, and prescribes only when they think it's the right call. Not everyone qualifies.

If the honest answer to "how long?" is "as long as it's earning its place, and we'll keep checking" — that isn't a dodge. It's what the evidence actually supports. Duration is also what turns a monthly price into a real total, which is the frame tesamorelin cost uses to compare brand and compounded prices.